Freeman Roy Lester
SEC insider (Form 3/4/5 filer). CIK 0001799732. Director at Inhibikase Therapeutics, Inc. (IKT). 16 reported Form 4/5 transactions since Sep 2024; latest on Feb 14, 2025. Located in ATLANTA, GA.
Companies Freeman Roy Lester has filed insider reports for
- Inhibikase Therapeutics, Inc. (IKT): Director
Freeman Roy Lester
CIK: 0001799732
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Inhibikase Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (16 total)
- Feb 14, 2025IKT
Inhibikase Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
22.6K shares- - Jan 21, 2025IKT
Inhibikase Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
21.9K shares- - Jan 21, 2025IKT
Inhibikase Therapeutics, Inc.
DispositionDirectStock Option (Right to Buy)
1.1K shares- - Jan 21, 2025IKT
Inhibikase Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
1.1K shares- - Jan 21, 2025IKT
Inhibikase Therapeutics, Inc.
DispositionDirectStock Option (Right to Buy)
3.8K shares- - Jan 21, 2025IKT
Inhibikase Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
3.8K shares- - Jan 21, 2025IKT
Inhibikase Therapeutics, Inc.
DispositionDirectStock Option (Right to Buy)
6.7K shares- - Jan 21, 2025IKT
Inhibikase Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
6.7K shares- - Jan 21, 2025IKT
Inhibikase Therapeutics, Inc.
DispositionDirectStock Option (Right to Buy)
21.9K shares- - Jan 21, 2025IKT
Inhibikase Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
6.7K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Feb 14, 2025 | IKT Inhibikase Therapeutics, Inc. | Award Stock Option (Right to Buy) | 22,640 | - | - | Direct |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | Award Stock Option (Right to Buy) | 21,854 | - | - | Direct |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | Disposition Stock Option (Right to Buy) | 1,138 | - | - | Direct |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | Award Stock Option (Right to Buy) | 1,138 | - | - | Direct |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | Disposition Stock Option (Right to Buy) | 3,780 | - | - | Direct |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | Award Stock Option (Right to Buy) | 3,780 | - | - | Direct |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | Disposition Stock Option (Right to Buy) | 6,667 | - | - | Direct |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | Award Stock Option (Right to Buy) | 6,667 | - | - | Direct |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | Disposition Stock Option (Right to Buy) | 21,854 | - | - | Direct |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | Award Stock Option (Right to Buy) | 6,667 | - | - | Direct |
1-10 of 16 transactions